211 reports of this reaction
1.3% of all ROCURONIUM BROMIDE reports
#17 most reported adverse reaction
CIRCULATORY COLLAPSE is the #17 most commonly reported adverse reaction for ROCURONIUM BROMIDE, manufactured by Fresenius Kabi USA, LLC. There are 211 FDA adverse event reports linking ROCURONIUM BROMIDE to CIRCULATORY COLLAPSE. This represents approximately 1.3% of all 16,854 adverse event reports for this drug.
Patients taking ROCURONIUM BROMIDE who experience circulatory collapse should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CIRCULATORY COLLAPSE is a less commonly reported adverse event for ROCURONIUM BROMIDE, but still significant enough to appear in the safety profile.
In addition to circulatory collapse, the following adverse reactions have been reported for ROCURONIUM BROMIDE:
The following drugs have also been linked to circulatory collapse in FDA adverse event reports:
CIRCULATORY COLLAPSE has been reported as an adverse event in 211 FDA reports for ROCURONIUM BROMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CIRCULATORY COLLAPSE accounts for approximately 1.3% of all adverse event reports for ROCURONIUM BROMIDE, making it a notable side effect.
If you experience circulatory collapse while taking ROCURONIUM BROMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.